Kernspintomografie bei Multipler Sklerose

Literatur

• 1 Allen I V, Glover G, Anderson R. Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis.  Acta Neuropathol. 1981;  7 176-178
• 2 Barkhof F, McGowan J C, van Waesberghe J H, Grossmann R I. Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: Their contribution in understanding multiple sclerosis evolution.  J Neurol Neurosurg Psych. 1998;  64 (1) 77-79
• 3 Barnes D, McDonald W I, Landon D N, Johnson G. The characterization of experimental gliosis by quantitative nuclear magnetic resonance imaging.  Brain. 1988;  111 83-94
• 4 Davie C A, Hawkins C P, Barker G J, Brennan A, Tofts P S, Miller D H, McDonald W I. Serial proton magnetic spectroscopy in acute multiple sclerosis lesions.  Brain. 1994;  117 49-58
• 5 Davie C A, Barker G J, Thompson A J, Tofts P S, McDonald W I, Miller D H. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis.  J Neurol. 1997;  63 736-742
• 6 De Stefano N, Matthews P M, Narayanan S, Francis G S, Antel J P, Arnold D L. Axonal dysfunction and disability in a relapse of multiple sclerosis: Longitudinal study of a patient.  Neurology. 1997;  49 1138-1141
• 7 Droogan A G, Clark C A, Werring D J, Barker G J, McDonald W I, Miller D H. Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging.  MRI. 1999;  17 653-661
• 8 Edwards S G, Gong Q Y, Liu C, Zwartau M E, Jaspan T, Roberts N, Blumhard L D. Infratentoriell atrophy on magnetic resonance imaging and disability in multiple sclerosis.  Brain. 1999;  122 291-301
• 9 European Study Group on Interferon β-1b in Secondary Progressive MS . Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis.  Lancet. 1998;  352 1491-1497
• 10 Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S, Lechner H. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis.  Neurology. 1988;  38 1822-1825
• 11 Fazekas F, Barkhof F, Filippi M, Grossmann R I, Li D K, McDonald W I, McFarland H F, Paty D W, Simon J H, Wolinsky J S, Miller D H. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis.  Neurology. 1999;  53 448-456
• 12 Filippi M, Rovaris M, Capra R, Gasperini C, Yousry T A, Sormani M P, Prandini F, Horsfield M A, Martinelli V, Bastianello S, Kuhne I, Pozilli C, Comi G. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolineum-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.  Brain. 1998;  121 2011-2020
• 13 Filippi M, Rocca M A, Rizzo G, Horsfield M A, Rovaris M, Minicucci L, Colomco B, Comi G. Magnetization transfer in multiple sclerosis lesions enhancing after different dosis of gadolineum.  Neurology. 1998;  50 1289-1293
• 14 Filippi M, Rovaris M, Bastianello S, Gasperini C, Origgi D, Reganati P, Pozilli C, Comi G. A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions.  J Neurol. 1999;  246 97-106
• 15 Fu L, Matthews P M, De Stefano N, Worsley K J, Narayanan S, Francis G S, Antel J P, Wolfson C, Arnold D L. Imaging axonal loss of normal-appearing white matter in multiple sclerosis.  Brain. 1998;  121 103-113
• 16 Gasperini C, Pozzilli C, Bastianello S, Koudriavtseva T, Galgani S, Millefiorini E, Paolillo A, Horsfield M A, Bozzao L, Fieschi C. Effect of steroids on gadolineum-enhancing lesions before and during recombinant beta interferon 1 a treatment in relapsing remitting multiple sclerosis.  Neurology. 1998;  50 403-406
• 17 Gass A, Radü E W, Filippi M, Kappos L. MRT-Verlaufsuntersuchungen bei Multipler Sklerose. Ein Leitfaden für die Qualitätssicherung.  Akt Radiol. 1999;  170 581-586
• 18 Goodkin D E, Rooney W D, Sloan R, Bacchetti P, Gee L, Vermathen M, Waubant E, Abundo M, Majumar S, Nelson S, Weiner M W. A serial study of new MS lesions and the white matter from which they arise.  Neurology. 1998;  51 1689-1697
• 19 Grossman R I. Magnetization transfer in multiple sclerosis.  Ann Neurol. 1994;  36 97-99
• 20 Hawkins C P, Munro P M, MacKenzie F, Kesselring J, Tofts P S, du Boulay E P, Landon D N, McDonald W I. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studies by gadolineum-DTPA and protein markers.  Brain. 1990;  113 365-378
• 21 Katz D, Taubenberger J K, Canella B, McFarlin D E, Raine C S, McFarland H F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis.  Ann Neurol. 1993;  34 661-669
• 22 Kermode A G, Thompson A J, Tofts P, McManus D J, Kendall B E, Kingsley D P, Moseley I F, Rudge P, McDonald W I. Breakdown of the blood brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.  Brain. 1990;  113 1477-1489
• 23 Kurtzke J F. Rating neurological impairment in multiple sclerosis: An expanded disability rating scale.  Neurology. 1983;  13 1444-1452
• 24 Lee K H, Hashimoto S A, Hooge J P, Kastrukoff L F, Oger J J, Li D K, Paty D W. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: A prospective 2-years follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal bands and CT.  Neurology. 1991;  41 657-660
• 25 Liu C, Edwards S, Gong Q, Roberts N, Blumhardt L D. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis.  J Neurol Neurosurg Psych. 1999;  66 323-330
• 26 Losseff N A, Webb S L, O¿Riordan J I, Page R, Wang L, Barker G J, Tofts P S, McDonald W I, Miller D H, Thompson A J. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression.  Brain. 1996;  119 701-708
• 27 Millefiorini E, Gasperini C, Pozzilli C, D¿Andrea F, Bastianello S, Trojano M, Morino S, Morra V B, Bozzao A, Calo A, Bernini M L, Gambini D, Prencipe M. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.  J Neurol. 1997;  244 153-159
• 28 Miller D F, Barkhof F, Nauta J J. Gadolineum enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis.  Brain. 1993;  116 1077-1094
• 29 Newcombe J, Hawkins C P, Henderson C L, Patel H A, Woodroofe M N, Hayes G M, Cuzner M L, MacManus D, du Bolay E P, McDonald W I. Histopathology of Multiple Sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous tissue.  Brain. 1991;  114 1013-1023
• 30 Noseworthy J H, Vandervoort M K, Wong C J, Ebers G C. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis trial. The Canadian Cooperation MS Study Group.  Neurology. 1990;  40 971-975
• 31 Offenbacher H, Fazekas F, Schmidt R, Freidl W, Flooh E, Payer F, Lechner H. Assessment of MRI criteria for a diagnosis of MS.  Neurology. 1993;  43 905-909
• 32 O¿Riordan J I, Thompson A J, Kingsley D P, MacManus D G, Kendall B E, Rudge P, McDonald W I, Miller D H. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.  Brain. 1998;  121 495-503
• 33 Poser C M, Paty D W, Scheinberg L C, McDonald W I, Davis F A, Ebers G C, Johnson K P, Sibley W A, Silberberg D H, Tourtelotte W W. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols.  Ann Neurol. 1983;  13 227-231
• 34 PRISMS Study Group . Randomised placebo-controlled double-blind study of interferon β-1a in relapsing/remitting multiple sclerosis.  Lancet. 1998;  352 1498-1504
• 35 Richert N D, Ostuni J L, Bash C N, Duyn J H, McFarland H F, Frank J A. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b.  AJNR. 1998;  19 1705-1713
• 36 Sarchielli P, Presciutti O, Tarducci R, Gobbi G, Alberti A, Pelliccioli G P, Orlacchio A, Gallai V. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study.  J Neurol Neurosurg Psych. 1998;  64 204-212
• 37 Smith M E, Stone L A, Albert P S, Frank J A, Martin R, Armstrong M, Maloni H, McFarlin D E, McFarland H F. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine enhancing magnetic resonance imaging lesions.  Ann Neurol. 1993;  33 480-489
• 38 Sorensen P S, Wanscher B, Jensen C V, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen V A, Lee M L. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.  Neurology. 1998;  50 1273-1281
• 39 The IFNB Multiple Sclerosis Study Group and the University of British Colombia MS/MRI Analysis Group . Interferon beta-1b in the treatment of multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial.  Neurology. 1995;  43 1277-1285
• 40 The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group . TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study.  Neurology. 1999;  53 457-465
• 41 Thompson A J, Kermode A G, Wicks D, MacManus D G, Kendall B E, Kingsley D P, McDonald W I. Major differences in the dynamics of primary and secondary progressive multiple sclerosis.  Ann Neurol. 1991;  29 53-62
• 42 Thompson A J, Miller D, Youl B, McManus D, Moore S, Kingsley D, Kendall B, Feinstein A, McDonald W I. Serial gadolineum enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration.  Neurology. 1992;  42 60-63
• 43 Thompson A J. Frühe Läsionen bei MS. In: Miller DH, Kesselring J, McDonald WI, Paty DW, Thompson AJ (Ed.): Magnetresonanz bei Multipler Sklerose. Kohlhammer, Stuttgart 1998: 128
• 44 Trapp B D, Peterson J, Ransohoff R M, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis.  New Engl J Med. 1998;  338 278-285
• 45 Van Walderveen M A, Kamphorst W, Scheltens P, van Waesberghe J H, Ravid R, Valk J, Polman C H, Barkhof F. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.  Neurology. 1998;  50 1282-1288
• 46 Van Walderveen M A, Truyen L, van Oosten B W, Castelijns J A, Lycklama a Nijeholt G J, van Waesberghe J H, Polman C, Barkhof F. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: Relation to inflammatory activity.  Arch Neurol. 1999;  56 345-351
• 47 Wolansky L J, Finden S G, Chang R, Conigliari M, Lee H J, Shaderowsky P D, Cook S D. Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging.  Clin Imaging. 1998;  22 385-392

Korrespondenz